版本:
中国

BRIEF-Amgen says new retrospective analyses confirm Vectibix treatment provided survival benefit over chemotherapy with or without Bevacizumab

Oct 10 Amgen Inc :

* New retrospective analyses confirm Vectibix (panitumumab) treatment provided survival benefit over chemotherapy with or without bevacizumab in metastatic colorectal cancer patients with tumors of left-sided origin Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐